Liver Function Tests in COVID-19: Assessment of the Actual Prognostic Value

Tokarczyk, Urszula; Kaliszewski, Krzysztof; Kopszak, Anna; Nowak, Łukasz; Sutkowska-Stępień, Karolina; Sroczyński, Maciej; Sępek, Monika; Dudek, Agata; Diakowska, Dorota; Trocha, Małgorzata; Gajecki, Damian; Gawryś, Jakub; Matys, Tomasz; Maciejiczek, Justyna; Kozub, Valeriia; Szalast, Roman; Madziarski, Marcin; Zarębska, Anna; Letachowicz, Krzysztof; Kiliś‐Pstrusińska, Katarzyna; Matera-Witkiewicz, Agnieszka; Pomorski, Michał; Protasiewicz, Marcin; Sokołowski, Janusz; Adamik, Barbara; Kujawa, Krzysztof; Doroszko, Adrian; Madziarska, Katarzyna; Jankowska, Ewa A.

doi:10.3390/jcm11154490

Cited by 5 publications

(4 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that elevated ALT, AST, and total bilirubin levels, but not elevated alkaline phosphatase levels, were associated either with COVID-19 mortality or risk of intubation. In another study from Poland involving 2184 patients, only an elevated AST level was associated with COVID-19-related mortality [ 26 ]. In this analysis too, alkaline phosphatase was not associated with COVID-19 outcomes.…”

Section: Discussionmentioning

confidence: 99%

Risk factors of SARS-CoV-2 infection and complications from COVID-19 in lung cancer patients

et al. 2023

View full text Add to dashboard Cite

Background Identifying lung cancer patients at an increased risk of getting SARS-CoV-2-related complications will facilitate tailored therapy to maximize the benefit of anti-cancer therapy, while decreasing the likelihood of COVID-19 complications. This analysis aimed to identify the characteristics of lung cancer patients that predict for increased risk of death or serious SARS-CoV-2 infection. Patients and methods This was a retrospective cohort study of patients with lung cancer diagnosed October 1, 2015, and December 1, 2020, and a diagnosis of COVID-19 between February 2, 2020, and December 1, 2020, within the Veterans Health Administration. Serious SARS-CoV-2 infection was defined as hospitalization, ICU admission, or mechanical ventilation or intubation within 2 weeks of COVID-19 diagnosis. For categorical variables, differences were assessed using Χ 2 tests, while Kruskal–Wallis rank-sum test was used for continuous variables. Multivariable logistic regression models were fit relative to onset of serious SARS-CoV-2 infection and death from SARS-CoV-2 infection. Results COVID-19 infection was diagnosed in 352 lung cancer patients. Of these, 61 patients (17.3%) died within four weeks of diagnosis with COVID-19, and 42 others (11.9%) experienced a severe infection. Patients who had fatal or severe infection were older and had lower hemoglobin levels than those with mild or moderate infection. Factors associated with death from SARS-CoV-2 infection included increasing age, immune checkpoint inhibitor therapy and low hemoglobin level. Conclusions The mortality of lung cancer patients from COVID-19 disease in the present cohort was less than previously reported in the literature. The identification of risk factors associated with severe or fatal outcomes informs management of patients with lung cancer who develop COVID-19 disease. Supplementary Information The online version contains supplementary material available at 10.1007/s10147-023-02311-3.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk factors of SARS-CoV-2 infection and complications from COVID-19 in lung cancer patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Liver enzyme abnormalities are frequent in patients with COVID-19 infection, and they are associated with disease severity[ 18 , 38 ]. The most frequently reported mild to moderate elevations were in aspartate aminotransferase (ALT), alanine aminotransferase (AST), and total bilirubin (tBIL) levels[ 35 ], but abnormal gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), and albumin levels have been found in patients with COVID-19 as well[ 18 , 22 , 39 ]. Liver damage in COVID-19 is usually temporary, and therefore, the enzyme levels of most patients usually return to normal after recovery[ 18 , 40 ].…”

Section: Prognostic Factors In Covid-19 Patients With Liver Diseasementioning

confidence: 99%

Outcomes of COVID-19 among patients with liver disease

Vujčić¹

2023

World J Gastroenterol

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is primarily a respiratory disease with multi-organ involvement, including impaired liver function. It has been noticed that a significant proportion of COVID-19 patients have liver dysfunction, especially those with a more severe disease course. The coronavirus causes direct damage to the liver using the angiotensin-converting enzyme 2, a cell-surface receptor for cellular entry, that is expressed in the liver. According to previous research, liver enzyme abnormalities were observed in a considerable proportion of COVID-19 patients, and elevated liver transaminases were found in about 20% of these patients, alkaline phosphatase in 6.1%, and gamma-glutamyl transferase in 21.1%. COVID-19 might trigger a deterioration of liver function in patients with pre-existing chronic liver diseases (CLDs) and also in those without previous liver disorders. The majority of COVID-19 patients who develop liver injury are men, the elderly, and those with a higher body mass index. Compared to the general population, COVID-19 is associated with significant morbidity and mortality in patients with liver disease (cirrhosis and liver transplantation recipients). However, some studies indicate that CLDs have a lesser role in determining patient progression towards higher disease severity.

show abstract

“…Although, Săbiescu et al [ 76 ] proved that only elevation over five times the upper limit is strongly correlated with high mortality risk. Also, hypoalbuminemia is a strong predictor of severe COVID-19 course and, in combination with AST or total bilirubin (TBIL), has a remarkable association with mortality[ 77 ], even in patients without chronic illness[ 78 ]. Furthermore, Da et al [ 79 ] reported a correlation between ALT levels and levels of inflammatory markers such as C-reactive protein, D-dimers, ferritin, and IL-6.…”

Section: Liver Manifestations Associated With Covid-19mentioning

confidence: 99%

Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients

Papa¹,

Covino²,

Lucia³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has several extrapulmonary symptoms. Gastrointestinal (GI) symptoms are among the most frequent clinical manifestations of COVID-19, with severe consequences reported in elderly patients. Furthermore, the impact of COVID-19 on patients with pre-existing digestive diseases still needs to be fully elucidated, particularly in the older population. This review aimed to investigate the impact of COVID-19 on the GI tract, liver, and pancreas in individuals with and without previous digestive diseases, with a particular focus on the elderly, highlighting the distinctive characteristics observed in this population. Finally, the effectiveness and adverse events of the anti-COVID-19 vaccination in patients with digestive disorders and the peculiarities found in the elderly are discussed.

show abstract

Liver Function Tests in COVID-19: Assessment of the Actual Prognostic Value

Cited by 5 publications

References 56 publications

Risk factors of SARS-CoV-2 infection and complications from COVID-19 in lung cancer patients

Risk factors of SARS-CoV-2 infection and complications from COVID-19 in lung cancer patients

Outcomes of COVID-19 among patients with liver disease

Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients

Contact Info

Product

Resources

About